AstraZeneca (LON:AZN) makes progress in the fight against liver cancer

The AstraZeneca (LON:AZN) share price idles despite the firm reporting positive results from its liver cancer clinical trials.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Syringe and vial on blue background

Image source: Getty Images

Last week, the AstraZeneca (LSE:AZN) share price didn’t move much despite exciting news emerging from its clinical trials. The company reported positive high-level results from its HIMALAYA phase three trial. Patients dosed with a combination of tremelimumab and durvalumab, two monoclonal antibodies, showed a statistically significant and meaningful improvement in overall survival against hepatocellular carcinoma.

That’s quite a mouthful. But in more simple terms, AstraZeneca has found a new combination of drugs that improves the odds of patients surviving a dominant form of liver cancer.

Why is this impressive?

Pharmaceutical companies have made enormous progress on cancer drugs over the last decade. Despite this, cancer continues to be the second leading cause of death worldwide. Liver cancer is currently the third most deadly, with approximately 900,000 people diagnosed each year.

According to a 2019 study published in the Digestive Diseases and Sciences journal, hepatocellular carcinoma is responsible for 75% of all liver cancer cases. And patients in the advanced stages of the disease only have a 7% chance of surviving longer than five years.

These latest trial results indicate this number is set to improve in the near future. That’s why the principal investigator, Ghassan Abou-Alfa, said,:“This is very exciting news for our patients.”

What it means for the AstraZeneca share price

In the short term, the AstraZeneca share price is unlikely to move on this news. But over the long term, if regulators approve this new drug regimen, the company could achieve substantial growth. According to Fortune Business Insights, the global liver cancer therapeutics market size is expected to grow by 20.2% annually until 2027, reaching over $7.3bn.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be considered so you should consider taking independent financial advice.

Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bearded man writing on notepad in front of computer
Investing Articles

Is there still time to buy Scottish Mortgage shares?

The Scottish Mortgage share price has risen strongly in recent weeks. Should I pile into the FTSE 100 momentum stock…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

Why I’d start buying shares with £250 today not £20,000 in future!

Is it worth waiting to start buying shares until one has more money to invest? Our writer doesn't think so…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

I’ve bought Diageo shares to boost my long-term passive income!

I plan to hold on to my Diageo shares well into retirement. Here's why I think it's a top stock…

Read more »

New virtual money concept, Gold Bitcoins
Investing Articles

Down 61%, are Argo Blockchain shares worth buying?

Argo Blockchain shares have tumbled in value. As a shareholder, Christopher Ruane considers what might come next for the business…

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

3 UK dividend stocks with yields over 10%

These dividend stocks are the highest yielders on the UK market, says Roland Head. But how safe are these generous…

Read more »

Couple relaxing on a beach in front of a sunset
Investing Articles

I’d start buying shares for passive income with this pair

Our writer is looking to earn passive income via investing, and here are two leading stocks he might buy.

Read more »

Tanker coming in to dock in calm waters and a clear sunset
Investing Articles

Here’s the Shell dividend forecast through to 2024

The Shell dividend is still nearly 50% below 2019 levels. Will the oil giant use record profits to rebuild its…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

3 FTSE 100 stocks I think Warren Buffett might love!

Warren Buffett made his fortune thanks to the success of US shares. But here are three FTSE 100 stocks I…

Read more »